Acetaminophen (Paracetamol) updated on 09-20-2024

ADHD (Attention deficit hyperactivity disorder): Diagnosis

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18555
R78889
Okubo (Controls unexposed, general population), 2025 Attention-deficit hyperactivity disorder (ADHD) - ICD-10 codes (F90 - diagnoses only or ADHD's medications) - Mean follow up 4.4 years during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes Paracetamol use: prescription or medical files 1.22 [1.06;1.41] -/42,123   -/42,123 - 42,123
ref
S18556
R78896
Okubo (Controls unexposed, sibling), 2025 Attention-deficit hyperactivity disorder (ADHD) - ICD-10 codes (diagnoses only or ADHD's medications) - Mean follow up 4.4 years during pregnancy (anytime or not specified) retrospective cohort (claims database) sibling excluded Adjustment: Yes Control group: Sibling Paracetamol use: prescription or medical files 0.86 [0.52;1.44]
excluded (control group)
-/11,696   -/11,897 - 11,696
ref
S18664
R79317
Pleau, 2025 Attention-deficit/hyperactivity disorder (ADHD) - (1) at least two dates with a diagnostic code of ADHD ; (2) at least two dates with a filled prescription for an ADHD medication or (3) at least one diagnosis of ADHD and one filled prescription for an ADHD medication - At least 2 years 2nd and/or 3rd trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes Paracetamol use: prescription or medical files 1.09 [0.94;1.27] 208/1,827   12,788/176,993 12,996 1,827
ref
S16629
R69722
Ahlqvist (Population-Based), 2024 Attention-deficit/hyperactivity disorder (ADHD) - ICD-10 (F90) or ICD-9 (314) - Median (IQR) follow-up of 13.4 (7.6-19.8) years during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Paracetamol use: maternal ITW/questionnaires during pregnancy 1.07 [1.05;1.10] 12,834/185,909   133,552/2,294,888 146,386 185,909
ref
S16630
R69728
Ahlqvist (Sibling), 2024 Attention-deficit/hyperactivity disorder (ADHD) - ICD-10 (F90) or ICD-9 (314) - Median (IQR) follow-up of 13.4 (7.6-19.8) years during pregnancy (anytime or not specified) population based cohort retrospective sibling excluded Adjustment: Yes Paracetamol use: maternal ITW/questionnaires during pregnancy 0.98 [0.94;1.02]
excluded (control group)
8,526/-   87,679/- 96,205 -
ref
S16639
R69757
Chen, 2019 Diagnoses of ADHD (ICD-9-CM code: 314) by board-certified psychiatrists on the basis of diagnostic interviews and clinical judgement - Age 0 - 15 years old (mean diagnosis 3.71) during pregnancy (anytime or not specified) nested case control unexposed (general population or NOS) Adjustment: Yes Paracetamol use: prescription or medical files 1.20 [1.01;1.42] 676/3,236   274/1,514 950 3,236
ref
S16655
R69967
Ystrom or Gustavson (Gustavson 2021 - Sibling), 2017 Attention deficit hyperactivity disorder - ICD-10 code F90 - Between 0 and 18 years old (Exposed >28 days) during pregnancy (anytime or not specified) prospective cohort sibling excluded Adjustment: Yes Paracetamol use: maternal ITW/questionnaires during pregnancy 2.02 [1.17;3.25]
excluded (control group)
-/469   -/12,080 - 469
ref
S16651
R69922
Ystrom or Gustavson (Ystrom - Population-Based), 2017 Attention-deficit/hyperactivity (ADHD - diagnosis of hyperkinetic disorder (F90.0, F90.1, F90.8, or F90.9)) - At 3-15 years old. during pregnancy (anytime or not specified) prospective cohort unexposed (general population or NOS) Adjustment: Yes Paracetamol use: maternal ITW/questionnaires during pregnancy 1.12 [1.02;1.24] -/52,707   -/60,266 - 52,707
ref
S16641
R69813
Liew, 2014 Hyperkinetic disorder diagnosis (ICD-10: F90.0-F90.9) - Mean age of children at the end of follow-up: 10.7 years (range, 8.2-13.4 years) during pregnancy (anytime or not specified) prospective cohort unexposed (general population or NOS) Adjustment: Yes Paracetamol use: maternal ITW/questionnaires during pregnancy 1.37 [1.19;1.59] 551/36,187   283/28,135 834 36,187
ref
Total 6 studies 1.16 [1.07;1.25] 161,166 321,989
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Okubo (Controls unexposed, general population), 2025Okubo, 2025 1 1.22[1.06; 1.41]-42,12314%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Pleau, 2025Pleau, 2025 1.09[0.94; 1.27]12,9961,82713%ROB confusion: moderateROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Ahlqvist (Population-Based), 2024Ahlqvist, 2024 2 1.07[1.05; 1.10]146,386185,90927%ROB confusion: moderateROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Chen, 2019Chen, 2019 1.20[1.01; 1.42]9503,23612%ROB confusion: moderateROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Ystrom or Gustavson (Ystrom - Population-Based), 2017Ystrom or Gustavson, 2017 3 1.12[1.02; 1.24]-52,70719%ROB confusion: moderateROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Liew, 2014Liew, 2014 1.37[1.19; 1.59]83436,18714%ROB confusion: moderateROB selection: lowROB classification: moderateROB missing: lowROB mesure: criticalROB reporting: moderate Total (6 studies) I2 = 68% 1.16[1.07; 1.25]161,166321,9890.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, general population; 2: Population-Based; 3: Ystrom - Population-Based;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.15[1.06; 1.25]160,216318,75372%NAOkubo (Controls unexposed, general population), 2025 Pleau, 2025 Ahlqvist (Population-Based), 2024 Ystrom or Gustavson (Ystrom - Population-Based), 2017 Liew, 2014 5 case control studiescase control studies 1.20[1.01; 1.42]9503,236 -NAChen, 2019 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.16[1.07; 1.25]161,166321,98968%NAOkubo (Controls unexposed, general population), 2025 Pleau, 2025 Ahlqvist (Population-Based), 2024 Chen, 2019 Ystrom or Gustavson (Ystrom - Population-Based), 2017 Liew, 2014 6 Tags Adjustment   - Yes  - Yes 1.16[1.07; 1.25]161,166321,98968%NAOkubo (Controls unexposed, general population), 2025 Pleau, 2025 Ahlqvist (Population-Based), 2024 Chen, 2019 Ystrom or Gustavson (Ystrom - Population-Based), 2017 Liew, 2014 6 Paracetamol use   - maternal ITW/questionnaires during ...  - maternal ITW/questionnaires during pregnancy 1.16[1.03; 1.30]147,220274,80383%NAAhlqvist (Population-Based), 2024 Ystrom or Gustavson (Ystrom - Population-Based), 2017 Liew, 2014 3   - prescription or medical files  - prescription or medical files 1.17[1.07; 1.28]13,94647,1860%NAOkubo (Controls unexposed, general population), 2025 Pleau, 2025 Chen, 2019 3 All studiesAll studies 1.16[1.07; 1.25]161,166321,98968%NAOkubo (Controls unexposed, general population), 2025 Pleau, 2025 Ahlqvist (Population-Based), 2024 Chen, 2019 Ystrom or Gustavson (Ystrom - Population-Based), 2017 Liew, 2014 60.55.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-0.40.40.1040.000Okubo (Controls unexposed, general population), 2025Pleau, 2025Ahlqvist (Population-Based), 2024Chen, 2019Ystrom or Gustavson (Ystrom - Population-Based), 2017Liew, 2014

Asymetry test p-value = 0.0497 (by Egger's regression)

slope=0.0454 (0.0180); intercept=1.8502 (0.6649); t=2.7826; p=0.0497

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 16655, 16630, 18556

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.16[1.07; 1.25]161,166321,98968%NAOkubo (Controls unexposed, general population), 2025 Pleau, 2025 Ahlqvist (Population-Based), 2024 Chen, 2019 Ystrom or Gustavson (Ystrom - Population-Based), 2017 Liew, 2014 6 siblingssiblings 1.15[0.76; 1.75]96,20512,16575%NAOkubo (Controls unexposed, sibling), 2025 Ahlqvist (Sibling), 2024 Ystrom or Gustavson (Gustavson 2021 - Sibling), 2017 30.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Bérard (Attention-Deficit Disorders With or W ...Bérard (Attention-Deficit Disorders With or Without Hyperactivity (ADHD) using diagnoses assessment) 1.16[1.05; 1.29]77%-Wwhatever (meta-analysis)Anyduring pregnancy (anytime or not specified)studies TTT4 metaPregmetaPreg 1.16[1.07; 1.25]68%321,989----Okubo (Controls unexposed, general population), 2025 Pleau, 2025 Ahlqvist (Population-Based), 2024 Chen, 2019 Ystrom or Gustavson (Ystrom - Population-Based), 2017 Liew, 2014 60.510.01.0